RE:RE:RE:RE:RE:Upped my anteWilli e Retiree, at $1.00 per share- I'd sell half. However, $160 million valuation for a cancer drug, even if only a second line of use, is rather a cheap evaluation. If Berentd and team can achieve what they say they will achieve, then I think that we would be $300 million to $500 million value. However, getting those approvaLs will not be a slam dunk.
Nuk, nuk